1. Induction therapy in multiple myeloma;Harousseau;Hematology Am Soc Hematol Educ Program,2008
2. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression;Mateos;Haematologica,2008
3. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008
4. San Miguel JF, Schlag R, Khuageva NK, et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalanprednisone in newly diagnosed multiple myeloma. Presented at: the 2008 meeting of the American Society of Hematology; December 7, 2008; San Francisco, CA. Abstract 650.
5. Harousseau J-L, Palumbo A, Richardson P, et al. Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone. Presented at: the 2008 meeting of the American Society of Hematology; December 7, 2008; San Francisco, CA. Abstract 2778.